Leerink Swann reaffirmed their outperform rating on shares of The Medicines Co. (NASDAQ:MDCO) in a report published on Saturday morning.
MDCO has been the subject of a number of other research reports. Cowen and Company reissued a buy rating and set a $45.00 price target on shares of The Medicines in a research report on Friday, August 5th. Jefferies Group reissued a buy rating and set a $43.00 price target on shares of The Medicines in a research report on Wednesday, August 31st. Guggenheim reissued a buy rating and set a $55.00 price target on shares of The Medicines in a research report on Monday, August 15th. Bank of America Corp. reissued a buy rating on shares of The Medicines in a research report on Tuesday, July 12th. Finally, Zacks Investment Research raised shares of The Medicines from a sell rating to a hold rating in a research report on Tuesday, July 12th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The Medicines currently has an average rating of Buy and a consensus target price of $47.33.
The Medicines (NASDAQ:MDCO) opened at 35.41 on Friday. The firm’s market capitalization is $2.47 billion. The Medicines has a 1-year low of $27.50 and a 1-year high of $43.00. The stock’s 50 day moving average is $38.65 and its 200-day moving average is $36.24.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.54. The Medicines had a negative net margin of 90.33% and a negative return on equity of 34.20%. The business earned $54.70 million during the quarter, compared to the consensus estimate of $41.93 million. During the same quarter last year, the company earned ($0.65) earnings per share. The business’s quarterly revenue was down 26.5% compared to the same quarter last year. Equities research analysts forecast that The Medicines will post ($1.36) EPS for the current year.
In other The Medicines news, Director Hiroaki Shigeta sold 3,849 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $38.50, for a total value of $148,186.50. Following the sale, the director now directly owns 23,547 shares in the company, valued at $906,559.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Clive Meanwell sold 8,623 shares of the firm’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $40.00, for a total value of $344,920.00. Following the completion of the sale, the chief executive officer now owns 347,791 shares in the company, valued at $13,911,640. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in The Medicines during the second quarter worth about $100,000. BlackRock Inc. boosted its stake in The Medicines by 28.3% in the first quarter. BlackRock Inc. now owns 4,554 shares of the company’s stock worth $145,000 after buying an additional 1,005 shares during the last quarter. Strs Ohio boosted its stake in The Medicines by 22.4% in the second quarter. Strs Ohio now owns 6,000 shares of the company’s stock worth $201,000 after buying an additional 1,100 shares during the last quarter. HBK Investments L P bought a new stake in The Medicines during the first quarter worth about $210,000. Finally, Emerald Acquisition Ltd. bought a new stake in The Medicines during the second quarter worth about $258,000.
The Medicines Company Profile